Page 209 - Read Online

Buerki et al. Biomarkers in glioma

gliomas and how they affect clinical practice. Neuro Oncol Pract clinical outcome in glioma. Br J Cancer 2014;110:2560-8.
2016; doi:10.1093/nop/npw016. 13. Rutledge WC, Kong J, Gao J, Gutman DA, Cooper LA, Appin C, Park
3. Binder DC, Davis AA, Wainwright DA. Immunotherapy for Y, Scarpace L, Mikkelsen T, Cohen ML, Aldape KD, McLendon RE,
cancer in the central nervous system: current and future directions. Lehman NL, Miller CR, Schniederjan MJ, Brennan CW, Saltz JH,
Oncoimmunology 2015;5:e1082027. Moreno CS, Brat DJ. Tumor-infiltrating lymphocytes in glioblastoma
4. Lukas RV, Wainwright DA, Laterra JJ. Updates from the Neuro- are associated with specific genomic alterations and related to
Oncology Section of the 2015 American Neurological Association transcriptional class. Clin Cancer Res 2013;19:4951-60.
Annual Meeting. Future Oncol 2016;12:143-7. 14. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson
5. Zhai L, Lauing KL, Chang AL, Dey M, Qian J, Cheng Y, Lesniak MS, SF, Liau LM. Gene expression profile correlates with T-cell infiltration
Wainwright DA. The role of IDO in brain tumor immunotherapy. J and relative survival in glioblastoma patients vaccinated with dendritic
Neurooncol 2015;123:395-403. cell immunotherapy. Clin Cancer Res 2011;17:1603-15.
6. Alexiou GA, Vartholomatos E, Zagorianakou P, Voulgaris S. 15. Han S, Liu Y, Li Q, Li Z, Hou H, Wu A. Pre-treatment neutrophil-to-
Prognostic significance of neutrophil-to-lymphocyte ratio in lymphocyte ratio is associated with neutrophil and T-cell infiltration
glioblastoma. Neuroimmunol Neuroinflammation 2014;1:131-4. and predicts clinical outcome in patients with glioblastoma. BMC
7. Alexiou GA, Kallinteri A, Nita E, Zagorianakou P, Levidiotou S, Cancer 2015;15:617.
Voulgaris S. Serum IgE levels in patients with intracranial tumors. 16. Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer
Neuroimmunol Neuroinflammation 2015;2:15-7. A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid
8. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M,
MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Wick W. Programmed death ligand 1 expression and tumor-infiltrating
Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross lymphocytes in glioblastoma. Neuro Oncol 2015;17:1064-75.
JG, Eisenhauer E, Mirimanoff RO; European Organisation for 17. Zhai L, Dey M, Lauing KL, Gritsina G, Kaur R, Lukas RV, Nicholas
Research and Treatment of Cancer Brain Tumor and Radiotherapy MK, Rademaker AW, Dostal CR, McCusker RH, Raizer JJ, Parsa AT,
Groups; National Cancer Institute of Canada Clinical Trials Group.
Radiotherapy plus concomitant and adjuvant temozolomide for Bloch O, Wainwright DA. The kynurenine to tryptophan ratio as a
glioblastoma. N Engl J Med 2005;352:987-96. prognostic tool for glioblastoma patients enrolling in immunotherapy.
9. Bambury RM, Teo MY, Power DG, Yusuf A, Murray S, Battley J Clin Neurosci 2015;22:1964-8.
JE, Drake C, O’Dea P, Bermingham N, Keohane C, Grossman SA, 18. McCarthy BJ, Rankin K, Il’yasova D, Erdal S, Vick N, Ali-Osman F,
Moylan EJ, O’Reilly S. The association of pre-treatment neutrophil to Bigner DD, Davis F. Assessment of type of allergy and antihistamine
lymphocyte ratio with overall survival in patients with glioblastoma use in the development of glioma. Cancer Epidemiol Biomarkers Prev
multiforme. J Neurooncol 2013;114:149-54. 2011;20:370-8.
10. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, 19. Wigertz A, Lönn S, Schwartzbaum J, Hall P, Auvinen A, Christensen
Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, HC, Johansen C, Klaeboe L, Salminen T, Schoemaker MJ, Swerdlow
Lacombe D, Stupp R. Nomograms for predicting survival of patients AJ, Tynes T, Feychting M. Allergic conditions and brain tumor risk.
with newly diagnosed glioblastoma: prognostic factor analysis Am J Epidemiol 2007;166:941-50.
of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 20. Huang RY, Neagu MR, Reardon DA, Wen PY. Pitfalls in the
2008;9:29-38. neuroimaging of glioblastoma in the era of antiangiogenic and
11. Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich immuno/targeted therapy - detecting illusive disease, defining
C, Campone MM, Twelves CC, Raymond E, Hegi ME, Lacombe D, response. Front Neurol 2015;6:33.
van den Bent MJ. New prognostic factors and calculators for outcome 21. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W,
prediction in patients with recurrent glioblastoma: a pooled analysis Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E,
of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson
Cancer 2012;48:1176-84. JH, Wen PY, Reardon DA. Immunotherapy response assessment in
12. Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y, Jiang T, Wu A. neuro-oncology: a report of the RANO working group. Lancet Oncol
Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of 2015;16:e534-42.

200 Neuroimmunology and Neuroinflammation ¦ Volume 3 ¦ September 26, 2016